Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nanobiotix (NBTX) Total Liabilities (2023 - 2025)

Nanobiotix has reported Total Liabilities over the past 3 years, most recently at $177.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 24.58% year-over-year to $177.2 million; the TTM value through Dec 2025 reached $177.2 million, up 24.58%, while the annual FY2025 figure was $177.2 million, 24.58% up from the prior year.
  • Total Liabilities for Q4 2025 was $177.2 million at Nanobiotix, up from $129.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $177.2 million in Q4 2025 and troughed at $103.0 million in Q4 2023.
  • A 3-year average of $133.7 million and a median of $129.2 million in 2025 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: soared 38.1% in 2024 and later increased 10.61% in 2025.
  • Year by year, Total Liabilities stood at $103.0 million in 2023, then soared by 38.1% to $142.3 million in 2024, then increased by 24.58% to $177.2 million in 2025.
  • Business Quant data shows Total Liabilities for NBTX at $177.2 million in Q4 2025, $129.2 million in Q2 2025, and $142.3 million in Q4 2024.